Join our daily newsletter At The Bell to receive exclusive market insights
- EMVision Medical Devices (EMV) reports all three of its clinical trial sites are now enrolling
- The Princess Alexandra Hospital sites in Brisbane are now live with the company reporting “excellent” maintenance of enrolment levels
- The company also reached another milestone under its project agreement with the ASA to obtain a further $600,000 non-dilutive milestone payment
- EMVision CEO and MD Scott Kirkland says the company has the vision to drive innovation in end-to-end stroke management
- EMV shares are up 2.89 per cent, trading at $1.25 at 11:33 am AEST
EMVision Medical Devices (EMV) has updated shareholders that all three of its clinical trial sites are now enrolling.
The company announced the Princess Alexandra Hospital sites in Brisbane are live with portable, noninvasive, affordable and safe neuroimaging devices in situ and has reported “excellent” maintenance of enrolment levels.
EMV also reached another milestone under its project agreement with the Australian Stroke Alliance (ASA) to obtain a further $600,000 non-dilutive milestone payment for its “Algorithm validation study – patient enrolment commenced” program.
The Australian Stroke Alliance (ASA) is funded by the Commonwealth of Australia’s Medical Research Future Fund (MRFF), and the milestone payment allows the company to continue with its novel therapies.
EMV CEO and Managing Director Scott Kirkland said the company had the vision to drive innovation in end-to-end stroke management and work with patient needs wherever the patient may be located.
“Our technology has the potential to enable earlier diagnosis in the acute phase and aid bedside post-treatment and intervention monitoring in a manner otherwise not possible today,” he said.
“We’re making good progress in our study, amassing critical data from both ‘front door’ and follow-up scans and we look forward to continuing accelerated enrolment into the study and reporting to the market of its progress”.
EMVision is hoping to generate the prerequisite data needed for major market regulatory submissions, including FDA.
EMV shares were up 2.89 per cent, trading at $1.25 at 11:33 am AEST.
